Skip to main content

Scientific Labs agrees to halt production of cough-cold medicines

5/20/2008

ROCKVILLE, Md. The Food and Drug Administration last week announced that Scientific Laboratories, and its president, Rajeshwari Patel, and chief executive officer, Amit Roy, have signed a Consent Decree of Permanent Injunction and are barred from manufacturing and distributing drug products until they bring their manufacturing operations into compliance with law and obtain approval for their products.

Scientific Laboratories is a contract manufacturer and distributor of various prescription cough and cold products. The government's complaint, filed by the U.S. Department of Justice, alleged that the company failed to seek required FDA approval for some of its products and failed to comply with current good manufacturing practice requirements.

“The FDA will not allow a company to put the public’s health at risk,” stated Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “These unapproved new drugs have not undergone FDA review for safety and efficacy and may pose potential health risks.”

The unapproved new drugs manufactured and marketed by Scientific Labs as prescription cough and cold products included: B-Vex Suspension, Ben-Tann Suspension, D-Tann Suspension, D-Tann AT Suspension, D-Tann CT Suspension, D-Tann DM Suspension, D-Tann HC Suspension, Dur-Tann DM Suspension, Duratan DM Suspension, L-All 12 Suspension, Nazarin Liquid, and Nazarin HC Liquid. Because these drugs have not undergone FDA review nor received approval, their safety and effectiveness have not been established. Additionally, the FDA has not reviewed the adequacy and accuracy of the directions and warnings in their labeling.

The decree was signed May 8 by Judge William Quarles, Jr., in the U.S. District Court for the District of Maryland.

X
This ad will auto-close in 10 seconds